AU775145B2 - Administration of non-oral androgenic steroids to women - Google Patents

Administration of non-oral androgenic steroids to women Download PDF

Info

Publication number
AU775145B2
AU775145B2 AU54758/00A AU5475800A AU775145B2 AU 775145 B2 AU775145 B2 AU 775145B2 AU 54758/00 A AU54758/00 A AU 54758/00A AU 5475800 A AU5475800 A AU 5475800A AU 775145 B2 AU775145 B2 AU 775145B2
Authority
AU
Australia
Prior art keywords
testosterone
dosage
achieve
sufficient
therapeutic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54758/00A
Other languages
English (en)
Other versions
AU5475800A (en
Inventor
Norman A. Mazer
Theresa Rosario-Jansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Finance LLC
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of AU5475800A publication Critical patent/AU5475800A/en
Application granted granted Critical
Publication of AU775145B2 publication Critical patent/AU775145B2/en
Priority to AU2004222794A priority Critical patent/AU2004222794B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU54758/00A 1999-06-11 2000-06-09 Administration of non-oral androgenic steroids to women Ceased AU775145B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004222794A AU2004222794B2 (en) 1999-06-11 2004-10-21 Non-oral androgenic steroids for women

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13932399P 1999-06-11 1999-06-11
US13885199P 1999-06-11 1999-06-11
US13885499P 1999-06-11 1999-06-11
US60/138854 1999-06-11
US60/138851 1999-06-11
US60/139323 1999-06-11
PCT/US2000/015834 WO2000076522A1 (en) 1999-06-11 2000-06-09 Administration of non-oral androgenic steroids to women

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004222794A Division AU2004222794B2 (en) 1999-06-11 2004-10-21 Non-oral androgenic steroids for women

Publications (2)

Publication Number Publication Date
AU5475800A AU5475800A (en) 2001-01-02
AU775145B2 true AU775145B2 (en) 2004-07-22

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54758/00A Ceased AU775145B2 (en) 1999-06-11 2000-06-09 Administration of non-oral androgenic steroids to women

Country Status (25)

Country Link
US (3) US6583129B1 (enExample)
EP (1) EP1189619A4 (enExample)
JP (2) JP5184727B2 (enExample)
KR (2) KR20020011437A (enExample)
CN (1) CN1220491C (enExample)
AR (1) AR024566A1 (enExample)
AU (1) AU775145B2 (enExample)
BR (1) BR0011740A (enExample)
CA (1) CA2376797C (enExample)
CO (1) CO5180583A1 (enExample)
CZ (1) CZ299198B6 (enExample)
HK (1) HK1048269B (enExample)
HU (1) HUP0301813A2 (enExample)
IL (1) IL147010A0 (enExample)
MX (1) MXPA01012769A (enExample)
MY (1) MY126960A (enExample)
NO (1) NO20016046L (enExample)
NZ (1) NZ516502A (enExample)
PE (1) PE20010404A1 (enExample)
PL (1) PL352250A1 (enExample)
SA (1) SA00210404B1 (enExample)
SK (1) SK18212001A3 (enExample)
TR (1) TR200200406T2 (enExample)
TW (1) TWI281398B (enExample)
WO (1) WO2000076522A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
TWI277418B (en) * 2001-06-18 2007-04-01 Noven Pharma Enhanced drug delivery in transdermal systems
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
CN1954807A (zh) * 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
MXPA04003866A (es) * 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
AU2003210759B2 (en) * 2002-04-03 2007-01-25 Barr Laboratories, Inc. Step-down estrogen therapy
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
AU2003221715A1 (en) * 2002-06-14 2003-12-31 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
DE602004030103D1 (de) * 2003-04-18 2010-12-30 Advanced Medicine Res Inst Mittel zur behanldung von krankheiten zur aufbringung auf das auge
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20080242726A1 (en) * 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
SG155258A1 (en) * 2004-10-20 2009-09-30 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
NZ556499A (en) * 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
AU2006218653A1 (en) * 2005-03-02 2006-09-08 Barnett, Gene Ph.D. Pharmaceutically acceptable carrier for ophthalmic compositions
KR20070114187A (ko) * 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
WO2007012815A1 (en) * 2005-07-27 2007-02-01 Ingenia Technology Limited Authenticity verification
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
ES2358619T3 (es) 2006-10-04 2011-05-12 M & P PATENT AKTIENGESELLSCHAFT Sistema de administración de liberación controlada para aplicación nasal de neurotransmisores.
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
EP2307026B1 (en) * 2008-07-04 2016-04-13 The Heart Research Institute Limited The use of androgens for vascular regeneration and endothelial repair
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
SG10201704221XA (en) 2012-12-05 2017-06-29 Ge Nutrients Inc Use of fenugreek extract to enhance female libido
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US20140274985A1 (en) * 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
ES2983874T3 (es) 2018-01-10 2024-10-25 Celista Pharmaceuticals Llc Pulverización transdérmica de testosterona con película
EP3817731B1 (en) 2018-07-05 2025-09-03 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
WO1998001115A1 (en) * 1996-07-10 1998-01-15 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
GB2320190A (en) * 1996-12-13 1998-06-17 Edmund Y M Chein Hormone replacement therapy involving human growth hormone (somatotropin)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210664A (en) 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
ES2261836T3 (es) * 1993-01-19 2006-11-16 Endorecherche Inc. Usos terapeuticos de dehidroepiandrosterona para tratamiento de libido disminuida y osteoporosis.
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
MXPA00012304A (es) 1998-06-11 2003-05-15 Endorech Inc Composiciones farmaceuticas y usos para el androst-5-ene-3beta, 17 beta-diol.
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
WO1998001115A1 (en) * 1996-07-10 1998-01-15 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
GB2320190A (en) * 1996-12-13 1998-06-17 Edmund Y M Chein Hormone replacement therapy involving human growth hormone (somatotropin)

Also Published As

Publication number Publication date
US6583129B1 (en) 2003-06-24
US20030153540A1 (en) 2003-08-14
CA2376797C (en) 2011-03-22
PE20010404A1 (es) 2001-04-09
NZ516502A (en) 2004-03-26
WO2000076522A1 (en) 2000-12-21
CZ20014499A3 (cs) 2002-05-15
KR20070063609A (ko) 2007-06-19
NO20016046L (no) 2002-02-06
HUP0301813A2 (hu) 2003-09-29
NO20016046D0 (no) 2001-12-11
US8551516B2 (en) 2013-10-08
HK1048269B (zh) 2006-01-13
BR0011740A (pt) 2002-05-14
CO5180583A1 (es) 2002-07-30
CN1220491C (zh) 2005-09-28
CZ299198B6 (cs) 2008-05-14
SA00210404B1 (ar) 2006-08-21
HK1048269A1 (en) 2003-03-28
TWI281398B (en) 2007-05-21
EP1189619A4 (en) 2004-06-09
SK18212001A3 (sk) 2002-04-04
CA2376797A1 (en) 2000-12-21
US20070190120A1 (en) 2007-08-16
CN1367698A (zh) 2002-09-04
AR024566A1 (es) 2002-10-16
JP5184727B2 (ja) 2013-04-17
MY126960A (en) 2006-11-30
EP1189619A1 (en) 2002-03-27
PL352250A1 (en) 2003-08-11
IL147010A0 (en) 2002-08-14
MXPA01012769A (es) 2003-06-24
US7186706B2 (en) 2007-03-06
TR200200406T2 (tr) 2002-06-21
KR20020011437A (ko) 2002-02-08
JP2013049682A (ja) 2013-03-14
AU5475800A (en) 2001-01-02
JP2003505345A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
AU775145B2 (en) Administration of non-oral androgenic steroids to women
AU2002245104B2 (en) Topical testosterone formulations and associated methods
CN100377711C (zh) 雄-5-烯-3β，17β-二醇的药物组合物及其用途
AU2002245104A1 (en) Topical testosterone formulations and associated methods
HU214598B (hu) Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására
US20060270642A1 (en) Method and apparatus for transdermal or transmucosal application of testosterone
AU6265998A (en) Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
RU2234920C2 (ru) Введение непероральным путем андрогенных стероидов женщинам
AU2004222794B2 (en) Non-oral androgenic steroids for women
US20080045486A1 (en) Ocular administration of testosterone
HK1088240A (en) The use of non-oral androgenic steroids in the manufacture of medicine for improving elevated sex hormone binding globulin levels
HK1078004B (en) PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β, 17β-DIOL
CN1739527A (zh) 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物